Sequential Afatinib and Osimertinib in Patients with <i>EGFR</i> Mutation-Positive Non-Small-Cell Lung Cancer: Final Analysis of the GioTag Study

Abstract

<b>Aim:</b> Final overall survival (OS) and time on treatment analysis of patients with <i>EGFR</i> mutation-positive non-small-cell lung cancer (NSCLC) who received sequential afatinib and osimertinib. <b>Patients & methods:</b> Patients (n = 203) had T790M-positive disease following first-line afatinib and started osimertinib treatment ≥10 months before data entry. Primary outcome was time on treatment; OS analysis was exploratory. <b>Results:</b> Median time on treatment with afatinib and osimertinib was 27.7 months (90% CI: 26.7-29.9). Median OS was 37.6 months (90% CI: 35.5-41.3); median OS was 41.6 and 44.8 months in Del19-positive patients and Asian patients, respectively. <b>Conclusion:</b> In real-world clinical practice, sequential afatinib and osimertinib was associated with encouraging outcomes in patients with <i>EGFR</i> mutation-positive NSCLC, especially in Del19-positive patients and Asian patients. <b>Clinical Trial Registration:</b> NCT03370770 (ClinicalTrials.gov).